Gonadotropin-releasing hormone agonist trigger increases the number of oocytes and embryos available for cryopreservation in cancer patients undergoing.

Slides:



Advertisements
Similar presentations
The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis 
Advertisements

Is the type of gonadotropin-releasing hormone suppression protocol for ovarian hyperstimulation associated with ectopic pregnancy in fresh autologous.
Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study  Thi.
Safety and feasibility of performing two consecutive ovarian stimulation cycles with the use of letrozole-gonadotropin protocol for fertility preservation.
Can pregnancy rate be improved in gonadotropin-releasing hormone (GnRH) antagonist cycles by administering GnRH agonist before oocyte retrieval? A prospective,
Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor.
1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for.
Ovarian stimulation to cryopreserve fertilized oocytes in cancer patients can be started in the luteal phase  Michael von Wolff, M.D., Christian J. Thaler,
Janet Kwee, M. D. , Roel Schats, M. D. , Ph. D. , Joseph McDonnell, M
Administration of a gonadotropin-releasing hormone antagonist during the 3 days before the initiation of the in vitro fertilization/intracytoplasmic sperm.
Clinical application of oocyte vitrification: a systematic review and meta-analysis of randomized controlled trials  Ana Cobo, Ph.D., César Diaz, M.D. 
Zhi-Yong Yang, M.D., Ri-Cheng Chian, Ph.D.  Fertility and Sterility 
Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3) in IVF patients with polycystic ovary syndrome: correlations with outcome 
Cem Atabekoglu, M. D. , Murat Sonmezer, M. D. , Sinan Özkavukcu, M. D
Ethnicity as a determinant of ovarian reserve: differences in ovarian aging between Spanish and Indian women  Carlos Iglesias, M.D., Manish Banker, M.D.,
Can an educational DVD improve the acceptability of elective single embryo transfer? A randomized controlled study  Nicole Hope, M.B., B.S., Hon., Luk.
Follicle-stimulating hormone administered at the time of human chorionic gonadotropin trigger improves oocyte developmental competence in in vitro fertilization.
Live birth of twins derived from zona-free oocytes
The role of antimullerian hormone in prediction of outcome after IVF: comparison with the antral follicle count  Simone L. Broer, B.Sc., Ben Willem J.
Anti-Müllerian hormone: correlation of early follicular, ovulatory and midluteal levels with ovarian response and cycle outcome in intracytoplasmic sperm.
How old is too old? Challenges faced by clinicians concerning age cutoffs for patients undergoing in vitro fertilization  Robert L. Klitzman, M.D.  Fertility.
Molly B. Moravek, M. D. , M. P. H. , Rafael Confino, B. S. , Kristin N
Oocyte cryopreservation
Do anti-mullerian hormone levels predict ovarian reserve in SLE patients presenting for hematopoietic stem cell transplant?  H. Browne, A. Armstrong,
Deleterious effect of tobacco on IVF outcome and ovarian reserve as reflected by serum anti mullerian hormone (AMH)  P. Barriere, T. Freour, D. Masson,
Oocyte cryopreservation outcomes including pre-cryopreservation and post-thaw meiotic spindle evaluation following slow cooling and vitrification of human.
Influence of acupuncture stimulation on pregnancy rates for women undergoing embryo transfer  Caroline Smith, Ph.D., Meaghan Coyle, B.Hlth.Sc. (Acup.),
A comparison of three downregulation approaches for poor responders undergoing in vitro fertilization  Laura Detti, M.D., Daniel B. Williams, M.D., Jared.
Ultrashort flare gonadotropin-releasing hormone (GnRH) agonist/GnRH antagonist protocol: a valuable tool in the armamentarium of ovulation induction for.
Comparison of luteal estradiol patch and gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation versus microdose.
The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis 
David E. Reichman, M.D., Dan Goldschlag, M.D., Zev Rosenwaks, M.D. 
Nigel Pereira, M. D. , Hency H. Patel, B. S. , Logan D. Stone, B. A
Duphaston and human menopausal gonadotropin protocol in normally ovulatory women undergoing controlled ovarian hyperstimulation during in vitro fertilization/intracytoplasmic.
Introduction Fertility and Sterility
Treatment of Ovarian Hyperstimulation Syndrome Utilizing a Dopamine Agonist and Gonadotropin Releasing Hormone antagonist  N. Rollene, M. Amols, S. Hudson,
Should embryos developing to blastocysts on day 7 be cryopreserved and transferred: an analysis of pregnancy and implantation rates  George Kovalevsky,
Nigel Pereira, Anna Voskuilen-Gonzalez, Kolbe Hancock, Jovana P
Akanksha Mehta, M.D., Darius A. Paduch, M.D., Ph.D. 
Lower apoptosis rate in human cumulus cells after administration of recombinant luteinizing hormone to women undergoing ovarian stimulation for in vitro.
Retrieval of immature oocytes after chemotherapy for Hodgkin's disease and prolonged ovarian down-regulation with gonadotropin-releasing hormone agonist 
Gonadotropin-releasing hormone antagonist use is associated with increased pregnancy rates in ovulation induction–intrauterine insemination to in vitro.
Changes in cytokine levels of patients with ovarian endometriosis after treatment with gonadotropin-releasing hormone analogue, ultrasound-guided drainage,
Clinical and endocrine response to the withdrawal of gonadotropin-releasing hormone agonists during prolonged coasting  Basil Ho Yuen, M.B., Ch.B., Tuan-Anh.
In vitro fertilization versus conversion to intrauterine insemination in the setting of three or fewer follicles: how should patients proceed when follicular.
Ri-Cheng Chian, Ph.D., Peter S. Uzelac, M.D., Geeta Nargund, M.D. 
Fertility and Sterility
A retrospective study on the use of dose-dependent letrozole to decrease cancer recurrence and adverse events in patients undergoing ovarian stimulation 
Jcoe Glenn Proctor, B.S., William R. Boone, Ph.D. 
Treatment of ovarian hyperstimulation syndrome using a dopamine agonist and gonadotropin releasing hormone antagonist: a case series  Nanette L. Rollene,
S. Samuel Kim, M.D.  Fertility and Sterility 
Pregnancy outcome in infertile patients with polycystic ovary syndrome who were treated with metformin  Samuel S. Thatcher, M.D., Ph.D., Elizabeth M.
Antimüllerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis.
L. Scott, J. Bernsten, K. DeLegge, J. Hill, N. Ramsing 
Cost-effectiveness comparison between pituitary down-regulation with a gonadotropin- releasing hormone agonist short regimen on alternate days and an antagonist.
Eric S. Surrey, M. D. , Debra A. Minjarez, M. D. , John M. Stevens, B
David H. Barad, M.D., M.S., Norbert Gleicher, M.D. 
Evaluating the role of exogenous luteinizing hormone in poor responders undergoing in vitro fertilization with gonadotropin-releasing hormone antagonists 
Comparing anti-Müllerian hormone (AMH) and follicle-stimulating hormone (FSH) as predictors of ovarian function  David H. Barad, M.D., M.S., Andrea Weghofer,
Comparison of a gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare-up regimen in poor responders undergoing ovarian stimulation 
Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study  Ahmed Badawy, M.D., Aboubakr.
Egg production predicts a doubling of in vitro fertilization pregnancy rates even within defined age and ovarian reserve categories  Melissa C. Yih, M.D.,
In vitro sildenafil citrate use as a sperm motility stimulant
Multiple fertility preservation approach in cancer patients: IVF and embryo freezing using donor or husband sperm combined with oocyte cryopreservation.
Which patients pursue fertility preservation treatments
Intrafollicular antimüllerian hormone levels predict follicle responsiveness to follicle- stimulating hormone (FSH) in normoandrogenic ovulatory women.
A novel “delayed start” protocol with gonadotropin-releasing hormone antagonist improves outcomes in poor responders  Hakan Cakmak, M.D., Nam D. Tran,
Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing.
In vitro viability and secretory capacity of human luteinized granulosa cells after gonadotropin-releasing hormone agonist trigger of oocyte maturation 
Comparisons of inhibin B versus antimüllerian hormone in poor ovarian responders undergoing in vitro fertilization  Rongrong Tan, M.M.Sc., Danhua Pu,
Presentation transcript:

Gonadotropin-releasing hormone agonist trigger increases the number of oocytes and embryos available for cryopreservation in cancer patients undergoing ovarian stimulation for fertility preservation  Nigel Pereira, M.D., Amelia G. Kelly, B.S., Logan D. Stone, B.A., Justine D. Witzke, Ph.D., M.P.H., Jovana P. Lekovich, M.D., Rony T. Elias, M.D., Glenn L. Schattman, M.D., Zev Rosenwaks, M.D.  Fertility and Sterility  Volume 108, Issue 3, Pages 532-538 (September 2017) DOI: 10.1016/j.fertnstert.2017.06.027 Copyright © 2017 American Society for Reproductive Medicine Terms and Conditions

Figure 1 Comparison of E2 to MII oocyte, gonadotropin to MII oocyte (A), MII oocyte to AMH, 2PN embryo to AMH, MII oocyte to AFC, and 2PN embryo to AFC (B) ratios in cancer patients undergoing ovarian stimulation with letrozole-based protocols (n = 269). Fertility and Sterility 2017 108, 532-538DOI: (10.1016/j.fertnstert.2017.06.027) Copyright © 2017 American Society for Reproductive Medicine Terms and Conditions

Figure 2 Comparison of E2 to MII oocyte, gonadotropin to MII oocyte (A), MII oocyte to AMH, and MII oocyte to AFC (B) ratios in cancer patients undergoing ovarian stimulation with gonadotropin-only protocols (n = 72). Fertility and Sterility 2017 108, 532-538DOI: (10.1016/j.fertnstert.2017.06.027) Copyright © 2017 American Society for Reproductive Medicine Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.